The Journal of Immunology, Vol 149, Issue 2 717-721, Copyright © 1992 by American Association of Immunologists

ARTICLES

Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination

D Valmori, A Pessi, E Bianchi and G Corradin
Institute of Biochemistry, University of Lausanne, Epalinges, Switzerland.

Synthetic constructs were assembled as multiple Ag peptide systems containing repetitive sequences of Plasmodium falciparum and Plasmodium berghei, the causative agents of human and murine malaria respectively, and two universal human tetanus toxin T cell epitopes 830-843 and 947- 967. These constructs were tested for antibody production in mice and for their capacity to stimulate human PBL and tetanus toxin-specific T cell clones. A high antibody titer can be obtained in mice when multiple Ag peptide systems are injected in various adjuvants or in PBS alone. Furthermore, all constructs can activate PBL from every donor tested. However, a variable response was obtained when different clones specific for the two tetanus toxin universal epitopes were used. These constructs may represent possible candidates for a malaria vaccine.

This article has been cited by other articles:

				S. HERRERA, A. BONELO, B. L. PERLAZA, O. L. FERNANDEZ, L. VICTORIA, A. M. LENIS, L. SOTO, H. HURTADO, L. M. ACUNA, J. D. VELEZ, et al. SAFETY AND ELICITATION OF HUMORAL AND CELLULAR RESPONSES IN COLOMBIAN MALARIA-NAIVE VOLUNTEERS BY A PLASMODIUM VIVAX CIRCUMSPOROZOITE PROTEIN-DERIVED SYNTHETIC VACCINE Am J Trop Med Hyg, November 1, 2005; 73(5_suppl): 3 - 9. [Abstract] [Full Text] [PDF]

				K. Baraldo, E. Mori, A. Bartoloni, F. Norelli, G. Grandi, R. Rappuoli, O. Finco, and G. Del Giudice Combined Conjugate Vaccines: Enhanced Immunogenicity with the N19 Polyepitope as a Carrier Protein Infect. Immun., September 1, 2005; 73(9): 5835 - 5841. [Abstract] [Full Text] [PDF]

				K. Baraldo, E. Mori, A. Bartoloni, R. Petracca, A. Giannozzi, F. Norelli, R. Rappuoli, G. Grandi, and G. Del Giudice N19 Polyepitope as a Carrier for Enhanced Immunogenicity and Protective Efficacy of Meningococcal Conjugate Vaccines Infect. Immun., August 1, 2004; 72(8): 4884 - 4887. [Abstract] [Full Text] [PDF]

				C. L. Slingluff Jr, G. R. Petroni, G. V. Yamshchikov, D. L. Barnd, S. Eastham, H. Galavotti, J. W. Patterson, D. H. Deacon, S. Hibbitts, D. Teates, et al. Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells J. Clin. Oncol., November 1, 2003; 21(21): 4016 - 4026. [Abstract] [Full Text] [PDF]

				H. Amir-Kroll, G. Nussbaum, and I. R. Cohen Proteins and Their Derived Peptides as Carriers in a Conjugate Vaccine for Streptococcus pneumoniae: Self-Heat Shock Protein 60 and Tetanus Toxoid J. Immunol., June 15, 2003; 170(12): 6165 - 6171. [Abstract] [Full Text] [PDF]

				L. Goetsch, J. F. Haeuw, T. Champion, C. Lacheny, T. N'Guyen, A. Beck, and N. Corvaia Identification of B- and T-Cell Epitopes of BB, a Carrier Protein Derived from the G Protein of Streptococcus Strain G148 Clin. Vaccine Immunol., January 1, 2003; 10(1): 125 - 132. [Abstract] [Full Text] [PDF]

				K. Peter, M. J. Brunda, and G. Corradin IL-12 Administration Leads to a Transient Depletion of T Cells, B Cells, and APCs and Concomitant Abrogation of the HLA-A2.1-Restricted CTL Response in Transgenic Mice J. Immunol., July 1, 2002; 169(1): 63 - 67. [Abstract] [Full Text] [PDF]

				M. A. Ostrowski, S. J. Justement, L. Ehler, S. B. Mizell, S. Lui, J. Mican, B. D. Walker, E. K. Thomas, R. Seder, and A. S. Fauci The Role of CD4+ T Cell Help and CD40 Ligand in the In Vitro Expansion of HIV-1-Specific Memory Cytotoxic CD8+ T Cell Responses J. Immunol., December 1, 2000; 165(11): 6133 - 6141. [Abstract] [Full Text] [PDF]

				I. Rauly, L. Goetsch, J.-F. Haeuw, C. Tardieux, T. Baussant, J.-Y. Bonnefoy, and N. Corvaia Carrier Properties of a Protein Derived from Outer Membrane Protein A of Klebsiella pneumoniae Infect. Immun., November 1, 1999; 67(11): 5547 - 5551. [Abstract] [Full Text] [PDF]

				Y. Charoenvit, V. F. Majam, G. Corradin, J. B. Sacci Jr., R. Wang, D. L. Doolan, T. R. Jones, E. Abot, M. E. Patarroyo, F. Guzman, et al. CD4+ T-Cell- and Gamma Interferon-Dependent Protection against Murine Malaria by Immunization with Linear Synthetic Peptides from a Plasmodium yoelii 17-Kilodalton Hepatocyte Erythrocyte Protein Infect. Immun., November 1, 1999; 67(11): 5604 - 5614. [Abstract] [Full Text] [PDF]

				S. Ghosh and D. C. Jackson Antigenic and immunogenic properties of totally synthetic peptide-based anti-fertility vaccines Int. Immunol., July 1, 1999; 11(7): 1103 - 1110. [Abstract] [Full Text] [PDF]

				S. Corradin, J. Mauel, A. Ransijn, C. Sturzinger, and G. Vergeres Down-regulation of MARCKS-related Protein (MRP) in Macrophages Infected with Leishmania J. Biol. Chem., June 11, 1999; 274(24): 16782 - 16787. [Abstract] [Full Text] [PDF]

				C. Yang, W. E. Collins, J. S. Sullivan, D. C. Kaslow, L. Xiao, and A. A. Lal Partial Protection against Plasmodium vivax Blood-Stage Infection in Saimiri Monkeys by Immunization with a Recombinant C-Terminal Fragment of Merozoite Surface Protein 1 in Block Copolymer Adjuvant Infect. Immun., January 1, 1999; 67(1): 342 - 349. [Abstract] [Full Text] [PDF]

				S. I. Becker, R. Wang, R. C. Hedstrom, J. C. Aguiar, T. R. Jones, S. L. Hoffman, and M. J. Gardner Protection of Mice against Plasmodium yoelii Sporozoite Challenge with P. yoelii Merozoite Surface Protein 1 DNA Vaccines Infect. Immun., July 1, 1998; 66(7): 3457 - 3461. [Abstract] [Full Text] [PDF]

				I. N. Foltz, R. E. Gerl, J. S. Wieler, M. Luckach, R. A. Salmon, and J. W. Schrader Human Mitogen-activated Protein Kinase Kinase 7 (MKK7) Is a Highly Conserved c-Jun N-terminal Kinase/Stress-activated Protein Kinase (JNK/SAPK) Activated by Environmental Stresses and Physiological Stimuli J. Biol. Chem., April 10, 1998; 273(15): 9344 - 9351. [Abstract] [Full Text] [PDF]